title: Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis.
abstract: OBJECTIVE
  This retrospective study aimed to investigate safety and efficacy of everolimus in patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease requiring dialysis.
  
  
  METHODS
  From November 2009 to December 2012, 11 mRCC patients undergoing dialysis were treated with everolimus after failure of anti-VEGF therapy at six Italian institutions. Patient characteristics, safety and outcomes were collected.
  
  
  RESULTS
  Progression-free survival and overall survival were determined using the Kaplan-Meier method. Median progression-free survival and overall survival were 9.01 and 15.7 months, respectively. No unexpected adverse events were reported.
  
  
  CONCLUSIONS
  Everolimus appears to be safe in mRCC patients with renal impairment or end-stage renal disease requiring dialysis. Larger prospective studies are required to confirm these findings.
authors.affiliation: Department of Oncology, Hematology & Respiratory Diseases, University of Modena & Reggio Emilia, Modena, Italy.
authors.forename: Annalisa
authors.initials: A
authors.lastname: Guida
authors.affiliation: AO Santa Maria Nuova, Reggio Emilia, Italy.|Italian Nephro-Oncology Group/Gruppo Italiano di Oncologia Nefrologica (GION), Italy.
authors.forename: Cristina
authors.initials: C
authors.lastname: Masini
authors.affiliation: Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy.
authors.forename: Michele
authors.initials: M
authors.lastname: Milella
authors.affiliation: Department of Endocrinology & Medical Oncology, Genitourinary Cancer Section, University Federico II, Napoli, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Di Lorenzo
authors.affiliation: Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti Umberto I, Ancona, Italy.
authors.forename: Matteo
authors.initials: M
authors.lastname: Santoni
authors.affiliation: Oncologia Medica a Direzione Universitaria, Fondazione del Piemonte per l'Oncologia, Istituto per la Ricerca e Cura del Cancan Candiolo, Torino, Italy.
authors.forename: Veronica
authors.initials: V
authors.lastname: Prati
authors.affiliation: Italian Nephro-Oncology Group/Gruppo Italiano di Oncologia Nefrologica (GION), Italy.|Medical Oncology, IRCCS San Matteo University Hospital Foundation, Pavia, Italy.
authors.forename: Camillo
authors.initials: C
authors.lastname: Porta
authors.affiliation: Italian Nephro-Oncology Group/Gruppo Italiano di Oncologia Nefrologica (GION), Italy.|UO Nefrologia e Dialisi, Azienda Istituti Ospitalieri di Cremona, Cremona, Italy.
authors.forename: Laura
authors.initials: L
authors.lastname: Cosmai
authors.affiliation: Unità Operativa Oncologia, Azienda Ospedaliero-Universitaria, Ferrara, Italy.
authors.forename: Donatella
authors.initials: D
authors.lastname: Donati
authors.affiliation: Statistics Unit, Department of Clinical, Diagnostic & Public Health Medicine, University of Modena & Reggio Emilia, Modena, Italy.
authors.forename: Cinzia
authors.initials: C
authors.lastname: del Giovane
authors.affiliation: Department of Oncology, Hematology & Respiratory Diseases, University of Modena & Reggio Emilia, Modena, Italy.
authors.forename: Pasquale
authors.initials: P
authors.lastname: Mighali
authors.affiliation: Department of Oncology, Hematology & Respiratory Diseases, University of Modena & Reggio Emilia, Modena, Italy.|Italian Nephro-Oncology Group/Gruppo Italiano di Oncologia Nefrologica (GION), Italy.
authors.forename: Roberto
authors.initials: R
authors.lastname: Sabbatini
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D003131:Combined Modality Therapy; D000068338:Everolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006435:Renal Dialysis / Q000379:methods; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D000068338:Everolimus
keywords: dialysis; everolimus; metastatic renal cell carcinoma